Journal
CYTOKINE & GROWTH FACTOR REVIEWS
Volume 18, Issue 5-6, Pages 491-501Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.cytogfr.2007.06.022
Keywords
APO2L/TRAIL; azacytidine; apoptosis
Categories
Funding
- NCI NIH HHS [R01 CA089091, CA89091] Funding Source: Medline
- NCRR NIH HHS [M01 RR018390, M01 RR018390-020001, M01 RR-018390] Funding Source: Medline
Ask authors/readers for more resources
Increased expression of genes, silenced by methylation of their promoters, could have relevance for increasing effects of not only interferons (IFNs) but also APO2L/TRAIL, cytotoxics and immunotherapeutics for melanoma and other malignancies. A resistant melanoma cell line, A375, lacked APO02L/TRAIL or apoptosis induction by either IFN-alpha 2 or IFN-beta. However, apoptosis was induced by IFNs in A375 cells by 5-aza,2'-deoxycytidine (5-Aza-dC), evaluated based upon the postulate that promoter methylation might be silencing pro-apopoptotic IFN-stimulated genes (ISGs). RASSF1A, commonly methylated at high frequency in many tumors including melanoma, which we discovered to be also an IFN-regulated gene, was increased by 5-Aza-dC. RASSF1 A was important in enhancing apoptotic effects of not only IFNs and APO2L/TRAIL but also cisplatin. Unraveling epigenetic regulatory mechanisms, as yet only partially identified, will result in new biological insights and improved strategies for therapeutic use of IFNs or ISGs such as APO2L/TRAIL. (c) 2007 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available